Fairmount Funds Management LLC - 17 Jun 2025 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
20 Jun 2025, 20:06:44 UTC
Prior SEC filing
23 Jun 2025
Next SEC filing
23 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 20 Jun 2025.

Key facts

  • This page summarizes Fairmount Funds Management LLC's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 20 Jun 2025, 20:06.

Change

  • Previous filing in this sequence was filed on 23 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship
Director
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Signature date
20 Jun 2025
CIK 0001830177

Kiselak Tomas

Relationship
Director
Address
2001 MARKET STREET, SUITE 2500, PHILADELPHIA
Signature
/s/ Tomas Kiselak
Signature date
20 Jun 2025
CIK 0001663607

Harwin Peter Evan

Relationship
Director
Address
2001 MARKET STREET, SUITE 2500, PHILADELPHIA
Signature
/s/ Peter Harwin
Signature date
20 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+14,461
Change %
Price
$0.000000
Shares after
14,461
Date
17 Jun 2025
Ownership
By: Peter Harwin
Underlying class
Common Stock
Underlying amount
14,461
Exercise price
$41.66
Footnotes
F1, F2
APGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+14,461
Change %
Price
$0.000000
Shares after
14,461
Date
17 Jun 2025
Ownership
By: Tomas Kiselak
Underlying class
Common Stock
Underlying amount
14,461
Exercise price
$41.66
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Footnote F2

Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Footnote F3

Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC remarks

Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .